ClinicalTrials.gg
Active, not recruitingNCT01701388EKSOUpdated Oct 22, 2026

EKSO Trial: Powered Exoskeleton for Ambulation in Subjects With Spinal Cord Injury (SCI)

An interventional study of Ekso exoskeleton in Spinal Cord Injuries or Similar Neurological Weakness, sponsored by Shirley Ryan AbilityLab. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2012, registered Aug 2012).
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Spinal Cord Injuries by Shirley Ryan AbilityLab — 12 open to participants now, 18 under way, none of them phase 3. Spinal Cord Injuries · Shirley Ryan AbilityLab.

Planned enrollment
23rd of 42
40 · median 45
Started
2012
with 1 other
No phase
33 of 45
8 open now
Primary completion
2027-12
later than 12 of 17 live
Registered
2nd of 45
by date

Among the 45 studies in Spinal Cord Injuries by Shirley Ryan AbilityLab, this one is the 23rd largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2012, is one of 33 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 2nd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 45 studies in Spinal Cord Injuries by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Spinal Cord Injuries by Shirley Ryan AbilityLab, or all of them as a file.
02

Study summary

This study seeks to test the safety and efficacy of the Esko device in SCI population and in populations with similar neurological weakness to the SCI population. The device can currently stand from a seated position, walk, and turn and sit down. Our hypothesis are as follows:

  • Hypothesis 1: We hypothesize that the Ekso subject will significantly improve balance while wearing the device as noted by subject's ability to safely achieve standing balance for 30 sec without loss of balance.
  • Hypothesis 2: We hypothesize that the Ekso subject will display improved ability to safely ambulate 10 meters to be assessed using the 10 meter walk test.
  • Hypothesis 3: We hypothesize that the Ekso subject will display improved weight shift in both static and dynamic activities as determined by a trained physical therapist.
  • Hypothesis 4: We hypothesize that the Ekso subject will verbalize improved success with training of the device as noted by subjective questionnaires that will be assessed following each training session.
Read the detailed description

This is an investigational clinical study trialing the safety and efficacy of the Esko device in the SCI population. Participants with a variety of spinal cord injury diagnoses (e.g. motor complete/incomplete, paraplegia/ tetraplegia) or diagnoses presenting with similar neurological weakness will be included to best determine the criteria for using the Ekso device within this population. The Ekso is an anthropomorphic mobile exoskeleton that is intended for spinal cord injury rehabilitation and mobility. The device is used to drive the patient's lower extremity joints through a desired trajectory in order to obtain a user specified motion.

The device is electrically powered by two motors at the knee and hip joints of either leg of the user. The flexion and extension directions at the hip and knee are only actuated degrees of freedom on the device. The device is equipped with mechanical hard stops at the limits of healthy subject ranges of motion to prevent powering the joint of the user to a position that the joint cannot reach. The device operates using a number of sensors. Some of these sensors are dedicated to maintaining proper function of the mechanical system and some are devoted to determining the user intent while using the device. The user focused sensors are foot pressure sensors at the heel and toe of both feet to determine the forces between the user and the ground at those locations.

The control code in the device behaves by creating an internal estimate of the subject's current position and then coordinating the motion of the four actuated degrees of freedom to take the desired motion. The desired motion is specified through an attached user interface that can be used by the patient or a therapist. The device can currently stand from a seated position, walk, and turn and sit down. In actual operation the device is triggered by one of two modes. The first mode is used early in training where the therapist manually triggers the steps of the user using the graphical interface; for advanced users, the machine interprets their motions to determine when steps are desired and the therapist is only responsible for starting and stopping the motion.

Complete and incomplete SCI patients as well as patients with similar neurological weakness will be recruited from inpatient, day rehab and outpatient clinics. Participants will be scheduled from 1-40 sessions. The amount of sessions provided will be dependent upon compatibility with device, ability to tolerate device use and ability to safely ambulate using the device. A participant will continue with each phase of the study as deemed appropriate by research staff:

  • A.Phase 1 (1-3 sessions): To determine if participant is compatible with device use. If participant is not compatible with device the study will stop here. If participant is compatible with device, subject will move into phase 2.
  • B.Phase 2 (4-10 sessions): Assessment and training of participant with device to determine safety and efficacy of subject with device. If subject is unsafe with device or does not tolerate device well then the study will stop here. If participant is safe, comfortable and efficient with device, participant will move into phase 3.
  • C.Phase 3 (11-40 sessions): Continued training with participant to determine functional ability of patient to use device within a lab or clinical environment.

All testing and training sessions will be under supervision of a licensed physical therapist. Manual assistance or cueing will be provided as necessary for safety and balance. Vital signs will be monitored before and after physical exertion. All subjects will be permitted to stop physical activity or rest at any time during the study. Adverse events will be recorded.

We anticipate this study will help to determine if the Ekso device is a feasible option to initiate ambulation in the motor complete SCI population, motor incomplete SCI population and other similar diagnostic populations unable to ambulate over ground. We do not foresee any potential pitfalls.

03

Conditions studied

  • Spinal Cord Injuries or Similar Neurological Weakness

Keywords

  • Ekso
  • Exoskeleton
  • Spinal Cord Injury
  • Motor Complete Incomplete
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must:

  • have a spinal cord injury SCI between C7-S1.
  • be between 18-65 years of age.
  • be able to physically fit into the exoskeletal device.
  • be able to tolerate upright standing for a minimum of 30 minutes.
  • have joint range of motion (ROM) within normal functional limits for ambulation.
  • have sufficient upper body strength to balance themselves using the walker while wearing the exoskeleton.
  • have a different neurological weakness than SCI but fit the other inclusion criteria above

Exclusion criteria

Exclusion Criteria:

  • Height below 62 inches or above 74 inches
  • Weight above 220 lbs.
  • Joint contractures of any extremity that limits normal ROM during ambulation with assistive devices.
  • Any medical issue that precludes full weight bearing and ambulation (e.g. orthopedic injuries, pain, severe spasticity)
  • Skin issues that would prevent wearing the device.
  • Cognitive and/or communicative disability (e.g. due to brain injury). Patients must be able to follow directions well and demonstrate learning capability.
  • Significant Osteoporosis: Osteoporosis will be graded based on the T score that indicates a person's bone mineral content and is graded as follows: (14)

T +1: Normal bone density:

  • T -1 to -2.5: Low bone density of osteopenia
  • T -2.5 to -3.0: osteoporosis
  • T \<-3.0: Severe osteoporosis
  • If the patient has severe osteoporosis and a T score of \<-3, participation in the study will be considered based upon their physicians recommendation and overall evaluation of the patient.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ekso Safety and Efficacy

    Observational study on the first time use of a robotic exoskeleton.

    Device: Ekso exoskeleton

Interventions

  • DeviceEkso exoskeleton

    The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.

    Also known as: Ekso by Eksobionics

06

What researchers measure

Primary outcomes

  1. Change in 6 Minute Walk Test from baseline in distance, rate of perceived exhaustion (RPE), and oxygen uptake

    The goal is to cover as much ground as possible over 6 minutes, the distance is measured with a measuring wheel. The instructions are "Walk continuously if possible, but do not be concerned if you need to slow down or stop to rest." At the end of 6 minutes the participant is asked to rate their exertion level on a Borg Scale of 6 - 20 points. The maximal oxygen consumption (VO2 MAX) data is collected during the test every 10 seconds

    Time frame: Testing Day 1 - 3 and follow up testing Week 6 and Week 12.

  2. Change in 10 meter walk test from baseline in gait speed

    Measure the time in second for and individual to walk 10 meters. The test is performed using a "flying start," patient walks 10 meters (33 ft) and the time is measured when the leading foot crosses the start line and the finish line. The instructions are: " Please walk this distance as fast as you safely can when I say go."

    Time frame: Testing Day 1 - 3 and follow up testing Week 6 and Week 12

Secondary outcomes

  1. Ratio of number of steps/walking time

    The data will be collected from the Ekso statistics mode \[data provided by the machine\]

    Time frame: Testing Day 1 - 3 and follow up testing Week 6 and Week 12.

  2. 2 Minute Walk Test

    Individual walks for 2 minutes and the distance is measured, start timing when the individual is instructed to "Go,"stop timing at 2 minutes, assistive devices can be used and documented from test to test, if physical assistance and/or tethering is required it will be recorded as well. The test should be performed at the fastest safest speed possible.

    Time frame: Testing Day 1 and follow up testing Week 6 and Week 12

  3. Walk time to stand time ratio on a particular assistive device

    The data will be collected from the statistics section of the Ekso. As patients progress from a rolling walker assistive device to the forearm crutches the ratio will be collected and compared to the initial and then final sessions with that particular device.

    Time frame: Testing Day 1 and follow up testing Week 6 and Week 12

Other outcomes

  1. Psychosocial Impact of Assistive Device Scale (PIADS)

    The PIADS is a 26-item, self-report questionnaire designed to assess the effects of an assistive device on functional independence, well-being, and quality of life. The PIADS can be used to assess the impact of any assistive device (AD), prosthesis or medical procedure. It can be used to evaluate the impact of ADs over time and to match the devices with consumers. With its excellent psychometric properties, the PIADS fills a missing link in the assessment of ADs as well as in the examination of their acceptance and abandonment.

    Time frame: Day 1- 3 after the first trial of the Ekso, follow up testing on Week 6 and Week 12

07

Study locations

1 site
  • Rehabilitation Institute of Chicago
    Chicago, Illinois 60611, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2012 (actual). Primary completion is estimated for Dec 2027, 187 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 187 months is above that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2012
First posted
Oct 5, 2012
StartActual
May 2012
Primary completionEst.
Dec 31, 2027was Dec 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2027
Oct 22, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Dec 31, 2025→Dec 31, 2027
    Study completion Dec 31, 2025→Dec 31, 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01701388
Collaborators
United States Department of Defense
Responsible party
Arun Jayaraman, PT, PhD (Research Scientist, Shirley Ryan AbilityLab) — Principal investigator
First posted
Oct 5, 2012
Start date
May 2012
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Arun Jayaraman, PhD
principal investigator · RIC/Northwestern

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion